VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
DBVT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
DBVTDBV Technologies S.A.
$15.61$924M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

DBVT logoDBV Technologies S.A.(DBVT)Earnings, Financials & Key Ratios

DBVT•NASDAQ
$15.61
Price updated Jul 6, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryImmunology and Inflammation Therapies
AboutDBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Show more
  • Revenue$0
  • EBITDA-$135M-19.2%
  • Net Income-$147M-29.6%
  • EPS (Diluted)-26.40-347.5%
  • ROE-150.29%-10.7%

DBVT Price & Volume

DBV Technologies S.A. (DBVT) stock price & volume — 10-year historical chart

Loading chart...

Clinical Development Costs Outpace Revenue Generation Potential

Investment Thesis • Updated 2026Q1

VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Regulatory approval and liquidity

Key Thesis Takeaways

  • DBV Technologies remains a high-risk, pre-revenue biotechnology firm entirely dependent on the successful regulatory progression of its Viaskin platform.
  • While the company maintains a cash position of $229.2 million as of 2026Q1, the persistent accumulation of $440.7 million in retained losses underscores the speculative nature of the investment.
  • Investors should monitor the company's ability to reach commercial milestones before the current cash runway is exhausted by quarterly R&D expenditures that reached $33.4 million in 2026Q1.

Verdict Logic

the company's reliance on speculative regulatory milestones and a persistent quarterly cash burn of $49.1 million in 2026Q1 suggest significant risk of further shareholder dilution.

DBVT Growth Metrics

DBV Technologies S.A. (DBVT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-
3 Years-
TTM-100%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-47.7%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM11.82%

Return on Capital

10 Years-80.79%
5 Years-87.77%
3 Years-107.22%
Last Year-145.72%

DBVT Recent Earnings

DBV Technologies S.A. (DBVT) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
Apr 30, 2026
Metric
Actual
Est
EPS
$0.56-300.0%
$0.14
Rev
$1M-4.9%
$1M
Q2 2026
Mar 27, 2026
Metric
Actual
Est
EPS
$1.15+11.5%
$1.30
Rev
$574,600-60.5%
$1M
Q2 2026
Mar 26, 2026
Metric
Actual
Est
EPS
$1.15+11.5%
$1.30
Rev
$574,600-60.5%
$1M
Q4 2025
Oct 28, 2025
Metric
Actual
Est
EPS
$1.20+17.2%
$1.45
Rev
$3M+204.5%
$1M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestApr 30, 2026
$0.56vs $0.14-300.0%
$1Mvs $1M-4.9%
Q2 2026Mar 27, 2026
$1.15vs $1.30+11.5%
$574,600vs $1M-60.5%
Q2 2026Mar 26, 2026
$1.15vs $1.30+11.5%
$574,600vs $1M-60.5%
Q4 2025Oct 28, 2025
$1.20vs $1.45+17.2%
$3Mvs $1M+204.5%
Based on last 12 quarters of dataView full earnings history →

Latest DBVT News

Recent stock market news and headlines for DBV Technologies S.A. (DBVT)

GlobeNewsWire·Jun 23, 2026
DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index

Châtillon, France, June 23, 2026 DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced that the Company has been included in the Euronext Tech Leaders index. Inclusion in the index went into effect on June 22, 2026.

Peers Comparison

Key metrics vs top competitors for DBV Technologies S.A. (DBVT)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
DBVT logoDBVTDBV Technologies S.A.Current
$15.61$923.9M-0.59——-150.29%—
ALKS logoALKSAlkermes plc
$55.14$9.19B38.56-5.25%9.78%8.82%—
PRGO logoPRGOPerrigo Company plc
$11.09$1.53B-1.08-2.75%-43.5%-50.65%—
SLRX logoSLRXSalarius Pharmaceuticals, Inc.
$0.74$697.79K-0.01——-117.81%—
SNGX logoSNGXSoligenix, Inc.
$0.38$3.97M-0.18——-246.04%—
HALO logoHALOHalozyme Therapeutics, Inc.
$80.78$9.58B31.5537.55%23.13%126.27%—

Compare DBVT vs Peers

DBV Technologies S.A. (DBVT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ALKS

Most directly comparable listed peer for DBVT.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare DBVT against a more recognizable public peer.

Peer Set

Compare Top 5

vs ALKS, PRGO, SLRX, SNGX

DBVT SEC Filings & Documents

DBV Technologies S.A. (DBVT) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Apr 30, 2026·SEC

Material company update

Mar 26, 2026·SEC

Material company update

Mar 2, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 26, 2026·SEC

FY 2024

Mar 7, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Apr 30, 2026·SEC

FY 2025

Oct 28, 2025·SEC

FY 2025

Jul 29, 2025·SEC

Get notified when DBVT posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

DBVT Frequently Asked Questions

DBV Technologies S.A. (DBVT) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
Is DBVT profitable?

DBV Technologies S.A. (DBVT) reported a net loss of $167.8M for fiscal year 2025.

Dividend & Returns
What is DBVT's return on equity?

DBV Technologies S.A. (DBVT) has a return on equity (ROE) of -150.3%. Negative ROE indicates the company is unprofitable.

What is DBV Technologies S.A.'s free cash flow?

DBV Technologies S.A. (DBVT) had negative free cash flow of $151.2M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in DBVT back in 2011?

Total return calculator · dividends reinvested · 15+ years of data

See returns →